The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor

Alessandro Gronchi, Jean Yves Blay, Jonathan C. Trent

Research output: Contribution to journalArticle

Abstract

After an era of few treatment options for patients with locally advanced or metastatic gastrointestinal stromal tumor (GIST), imatinib has emerged as the standard of care and first-line treatment for these patients. Although imatinib was initially approved at the doses of 400 and 600 mg daily, results from clinical studies established 400 mg daily as the standard initial dose for the majority of advanced GIST patients. Nevertheless, the use of high-dose imatinib (800 mg daily) has been shown to benefit patients with advanced or metastatic GIST that progresses on the standard-dose, and has been recommended in this setting by the major management guidelines in Europe and the United States. Results from the Meta-GIST meta-analysis showed that patients whose GIST harbors a KIT exon 9 mutation garner a longer progression-free survival time when treated initially with high-dose imatinib (800 mg daily) compared with those patients with KIT exon 11 or no mutations. Thus, the use of high-dose imatinib is recommended by the clinical practice guidelines in these 2 specific clinical situations. In addition, clinicians should weigh the clinical benefit of administering high-dose imatinib against the associated toxicities, as well as the proper management of dose-related side effects.

Original languageEnglish
Pages (from-to)1847-1858
Number of pages12
JournalCancer
Volume116
Issue number8
DOIs
Publication statusPublished - Apr 15 2010

Fingerprint

Gastrointestinal Stromal Tumors
Exons
Mutation
Standard of Care
Practice Guidelines
Disease-Free Survival
Meta-Analysis
Imatinib Mesylate
Guidelines
Therapeutics

Keywords

  • Gastrointestinal stromal tumor
  • GIST
  • Gleevec
  • Glivec
  • High-dose
  • Imatinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. / Gronchi, Alessandro; Blay, Jean Yves; Trent, Jonathan C.

In: Cancer, Vol. 116, No. 8, 15.04.2010, p. 1847-1858.

Research output: Contribution to journalArticle

Gronchi, Alessandro ; Blay, Jean Yves ; Trent, Jonathan C. / The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. In: Cancer. 2010 ; Vol. 116, No. 8. pp. 1847-1858.
@article{63ce32bb078049c2a7c69eff1a116c6b,
title = "The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor",
abstract = "After an era of few treatment options for patients with locally advanced or metastatic gastrointestinal stromal tumor (GIST), imatinib has emerged as the standard of care and first-line treatment for these patients. Although imatinib was initially approved at the doses of 400 and 600 mg daily, results from clinical studies established 400 mg daily as the standard initial dose for the majority of advanced GIST patients. Nevertheless, the use of high-dose imatinib (800 mg daily) has been shown to benefit patients with advanced or metastatic GIST that progresses on the standard-dose, and has been recommended in this setting by the major management guidelines in Europe and the United States. Results from the Meta-GIST meta-analysis showed that patients whose GIST harbors a KIT exon 9 mutation garner a longer progression-free survival time when treated initially with high-dose imatinib (800 mg daily) compared with those patients with KIT exon 11 or no mutations. Thus, the use of high-dose imatinib is recommended by the clinical practice guidelines in these 2 specific clinical situations. In addition, clinicians should weigh the clinical benefit of administering high-dose imatinib against the associated toxicities, as well as the proper management of dose-related side effects.",
keywords = "Gastrointestinal stromal tumor, GIST, Gleevec, Glivec, High-dose, Imatinib",
author = "Alessandro Gronchi and Blay, {Jean Yves} and Trent, {Jonathan C.}",
year = "2010",
month = "4",
day = "15",
doi = "10.1002/cncr.24944",
language = "English",
volume = "116",
pages = "1847--1858",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor

AU - Gronchi, Alessandro

AU - Blay, Jean Yves

AU - Trent, Jonathan C.

PY - 2010/4/15

Y1 - 2010/4/15

N2 - After an era of few treatment options for patients with locally advanced or metastatic gastrointestinal stromal tumor (GIST), imatinib has emerged as the standard of care and first-line treatment for these patients. Although imatinib was initially approved at the doses of 400 and 600 mg daily, results from clinical studies established 400 mg daily as the standard initial dose for the majority of advanced GIST patients. Nevertheless, the use of high-dose imatinib (800 mg daily) has been shown to benefit patients with advanced or metastatic GIST that progresses on the standard-dose, and has been recommended in this setting by the major management guidelines in Europe and the United States. Results from the Meta-GIST meta-analysis showed that patients whose GIST harbors a KIT exon 9 mutation garner a longer progression-free survival time when treated initially with high-dose imatinib (800 mg daily) compared with those patients with KIT exon 11 or no mutations. Thus, the use of high-dose imatinib is recommended by the clinical practice guidelines in these 2 specific clinical situations. In addition, clinicians should weigh the clinical benefit of administering high-dose imatinib against the associated toxicities, as well as the proper management of dose-related side effects.

AB - After an era of few treatment options for patients with locally advanced or metastatic gastrointestinal stromal tumor (GIST), imatinib has emerged as the standard of care and first-line treatment for these patients. Although imatinib was initially approved at the doses of 400 and 600 mg daily, results from clinical studies established 400 mg daily as the standard initial dose for the majority of advanced GIST patients. Nevertheless, the use of high-dose imatinib (800 mg daily) has been shown to benefit patients with advanced or metastatic GIST that progresses on the standard-dose, and has been recommended in this setting by the major management guidelines in Europe and the United States. Results from the Meta-GIST meta-analysis showed that patients whose GIST harbors a KIT exon 9 mutation garner a longer progression-free survival time when treated initially with high-dose imatinib (800 mg daily) compared with those patients with KIT exon 11 or no mutations. Thus, the use of high-dose imatinib is recommended by the clinical practice guidelines in these 2 specific clinical situations. In addition, clinicians should weigh the clinical benefit of administering high-dose imatinib against the associated toxicities, as well as the proper management of dose-related side effects.

KW - Gastrointestinal stromal tumor

KW - GIST

KW - Gleevec

KW - Glivec

KW - High-dose

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=77951007582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951007582&partnerID=8YFLogxK

U2 - 10.1002/cncr.24944

DO - 10.1002/cncr.24944

M3 - Article

C2 - 20166214

AN - SCOPUS:77951007582

VL - 116

SP - 1847

EP - 1858

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -